BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review ...Middle East

STOCKHOLM, June 13, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that the interim safety review of the clinical Phase 2a study EXIST showed exidavnemab to be safe and well-tolerated, whereby the second dose cohorts will now be initiated. The EXIST...

Read More Details
Finally We wish PressBee provided you with enough information of ( BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review )

Also on site :

• ‘90s Country Star, 60, Shows off Slimmed Down Look at Intimate Show: ‘Beautiful'
• 2 HGTV Stars Turn Heads In Cheeky Bikinis
• Riverside County pays $1.3 million to Wildomar man whose face was broken by deputies